The research for the adherence and QOL for oral anti-coagulants(OAC) in patients with atrial fibrillation

Trial Profile

The research for the adherence and QOL for oral anti-coagulants(OAC) in patients with atrial fibrillation

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2015

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Sponsors Bayer Yakuhin
  • Most Recent Events

    • 13 Mar 2015 Status changed from recruiting to completed as per University Hospital Medical Information Network record.
    • 24 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top